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study liMitations: Loss of some monthly laboratory sample collection. 
conclusions: There was no statistical difference regarding adverse effects in the R-MDT and U-MDT groups but anemia was 
greater	 in	patients	 from	R-MDT/MB	group,	 therefore	adverse	effects	do	not	represent	a	constraint	 to	recommend	the	six-






(MDT),	 recommended	 by	WHO	 in	 1981,	 is	 based	 on	 the	 combi-
nation	 of	 drugs:	 dapsone	 and	 rifampin	 for	 patients	 classified	 as	
paucibacillary	 (PB),	 and	dapsone,	 rifampicin	 and	 clofazimine	 for	
multibacillary	patients	(MB).1	Since	1982,	millions	of	patients	were	
treated	and	cured	with	MDT	and	report	of	adverse	effects	(AE)	is	
considerably	 low	when	 compared	 to	 the	benefit	 for	patients	 and	
Leprosy Control Programs.2
However,	AE	caused	by	these	drugs	can	be	severe	and	dis-
continuation of treatment should be necessary in some patients. 
Dapsone	 alone	 can	 cause	methemoglobinemia,	 hemolytic	 anemia	
and	other	haematological	disorders.	Hepatitis,	pancreatitis,	and	re-











In	 order	 to	 implement	 leprosy	 control	 in	 the	 field,	WHO	
has made changes in the treatment duration. The number of doses 




doses for MB patients.10	Despite	 the	MDT	success,	 the	 long	 treat-
ment	duration,	the	difficulty	to	implement	treatment,	and	the	low	
adherence	 for	 treatment,	 reinforces	 the	need	for	shorter	 treatment	
regimen.11,12	 In	 2002,	 the	WHO	Leprosy	Expert	Committee recom-
mended pilot trials to evaluate the possibility of a uniform MDT 
regimen	(U-MDT)	with	6	doses	of	MDT-MB	for	all	leprosy	patients,	
independently	of	any	classification.13
A	multicenter	 clinical	 trial	 to	 assess	 the	 effectiveness	 of	 a	
U-MDT regimen was initiated in India and China in 2004.14 Up to 
now,	clinical	improvement	of	PB	patients,	and	good	acceptability	of	
MB	patients	are	 the	main	aspects	observed.	Moreover,	 the	regimen	
was	 easier	 to	 implement	 in	general	 health	 services.	Another	 study	
conducted	in	India,	concluded	that	the	U-MDT	was	effective	for	treat-
ment	of	PB	patients	but	the	follow	up	was	not	adequate	to	evaluate	
the	 efficacy	 for	MB	patients	 and	 it	was	not	 compared	with	MDT/
WHO. 15 No increase of relapses among MB patients treated with 
U-MDT was observed in a recent study conducted in Bangladesh.16
To evaluate the effectiveness of the new treatment regimen 
(U-MDT)	for	leprosy	patients,	an	open-label,	randomized	and	con-
trolled clinical trial - (Clinical Trial for Uniform Multidrug Therapy for 









different groups and treatment regimens.
METHODS
A	total	of	753	patients	were	recruited	 from	March	2007	 to	
February	 2012,	 at	 two	National	 Brazilian	 referral	 leprosy	 centers:	
Dona	 Libânia	 (Fortaleza,	 Ceará)	 and	Alfredo	 da	Matta	 (Manaus,	
Amazonas).	 Patients	 were	 classified	 as	 PB	 and	 MB	 according	 to	
the	 number	 of	 skin	 lesions	 and	 randomly	 assigned	 to	U-MDT	or	
R-MDT	sub-groups.	Further	protocol	details	may	be	found	in	“Clin-
ical Trial for Uniform Multidrug Therapy for Leprosy Patients in 
Brazil	(U-MDT/CT-BR):	Rationale	and	Design”	with	open-access	at	
the site.17










about leprosy reactions and adverse effects; this information was 
registered	on	the	Clinical	Registration	Forms	(CRF).	Patients	were	
encouraged to return at any time in case of any abnormality. The 
main	 adverse	 effects	were	 characterized	 as	 follows:	Anemia	 -	de-
crease	 of	 hemoglobin	 from	 baseline	 (less	 than	 10g/dL),	 and	 the	
possibility	of	association	with	fatigue,	dyspnea,	dizziness	and	jaun-
dice;	methemoglobinemia	 –	 presence	 of	 cyanosis,	 dyspnea,	 dizzi-
ness,	headache	and/or	fatigue;	psychiatric	disorders	-	depression,	
psychotic	 or	 anxiety	 behavior;	 xerosis	 -	 dryness	 of	 the	 skin,	with	
or	without	pruritus	and	scaling;	skin	pigmentation:	darkness	of	the	
skin;	erythroderma	–	erythematous	eruption	extending	to	over	90%	
of	 the	 body	 surface;	 urticaria	 -	 edematous	 itchy	 plaques,	with	 or	
without	 angioedema;	 dapsone	 syndrome	 -	 exfoliative	 dermatitis,	
accompanied	 by	 fever,	 hepatosplenomegaly	 and	 liver	 functions	
abnormalities;	 flu-like	 syndrome	 -	 fever,	 runny	 nose,	 sore	 throat,	
cough,	 nausea,	 vomiting,	 poor	 appetite,	 headache,	 muscle/joint	
aches,	and	malaise;	hepatotoxicity,	mild - serum aminotransferases 
levels from 40 IU/l to 100 IU/l; moderate to severe - aminotransferas-
es	over	100	IU/l,	with	or	without	clinical	evidence	of	jaundice,	mal-
aise	and	other	symptom.	The	criteria	for	mild,	moderate	or	severe	
for each side-effect were based on the U.S. National Cancer Institute 
- Cancer Therapy Evaluation Program, Common Terminology Criteria for 
Adverse Events, version 3.0, see. Protocolo MDTU- Rationale and Design 






tored and evaluated twelve times as the MB/R-MDT patients that 
received	12	MDT	doses.	Therefore,	 the	13th blood collection corre-
sponds to 210 days after the last MDT dose for MB/U-MDT patients 
and 30 days for MB/R-MDT patients.
Ethical considerations
The study was performed under the International (Helsin-
ki)	 and	Brazilian	 research	 regulations	 involving	humans	and	was	
approved on the 17th	February	2006,	(protocol	001/06)	by	the	ethical	
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*For	treatment	purpose,	recruited	patients	were	classified	based	on	number	of	skin	lesions,	up	to	five	lesions	as	PB	and	or	mores	lesions	as	MB.
table 1:  Baseline characteristics of 753 leprosy patients, according to treatment groups
Characteristics Paucibacillary Multibacillary
TOTAL
Mean age / Age group U-MDT 41.44 R-MDT 36.08 U-MDT 42.16 R-MDT 41.44
0 – 9 1 1.3% 2 2.4% 5 1.6% 6 	2.2% 14	(1.9%)
10 – 19 9 11.7% 17 20.7% 25 7.8% 24 8.8% 75	(10.0%)
20 – 29 12 15.6% 13 15.9% 65 20.2% 45 16.5% 135		(17.9%)
30 – 39 21 27.3% 18 22.0% 59 18.4% 52 19.0% 150		(19.9%)
40 – 49 11 14.3% 19 23.2% 68 21.2% 63 23.1% 161		(21.4%)
50 – 59 18 23.4% 10 12.2% 68 21.2% 63 23.1% 159		(21.1%)
60 – 69 5 	6.5% 3 	3.7% 31 	9.7% 20 		7.3% 59	(7.8%)
Sex
Male 25 32.5% 29 35.4% 215 67.0% 179 65.6% 448	(59.5%)
Female 52 67.5% 53 64.6% 106 33.0%  94 34.4% 305	(40.5%)
IB
0 71 92.2% 80 97.6% 96 29.9% 80 29.3% 327	(43.4%)
0.1 – 2.99 6* 7.8% 2* 2.4% 75 23.4% 61 22.3% 144	(19.1%)
>	3 0 0% 0 0% 150 46.7% 132 48.4% 282	(37.5%)
Total 77 10.2% 82  10.9% 321 42.6% 273 36.3% 753
committees of the two institutions involved in the research and the 
National Ethics Commission. Written informed consent was ob-
tained from all the patients. Written parental consent was obtained 
for	patients	with	6	to	17	years	old.	Data	confidentiality	was	guaran-
teed and the patients were free to leave the study at any time during 
the	trial	(ClinicalTrials.gov	identifier	-	NCT00669643).
Statistical analysis 
The following hematological values were used as normal 
parameters: red blood cells – minimum of 4.4 million cells for male 
and 4.2 million for female; hemoglobin – 13g/dL for male and 12g/
dL	for	female;	hematocrit	–	43%	for	male	and	37%	for	female;	leuko-
cytes:	3,600	uL,	MCHC:	30	-	35g/dL	(%),	MCV:	80	-	95	fL	and	MCH:	
27 - 34 pg. 18,19
Data	 are	 expressed	 as	 mean	 ±	 SD.	 Analysis	 of	 Variance	






















changes	 (>40)	 in	GOT	and	GPT	values,	without	 statistical	 signifi-
cance. GTP and GOT were above 100 at any time during the treat-






in	 201(26.7%)	 patients	 but	 there	was	 no	 significant	 difference	 be-
tween	the	U-MDT	and	the	R-MDT	groups	(p	=	0.2242).	With	the	ex-
ception	of	leukocytes	and	MCV	hematological	parameters,	all	oth-
ers presented lower average for the PB/U-MDT compared to other 
groups. The hematological averages were higher for MB/U-MDT 
group,	receiving	6	doses,	than	the	MB/R-MDT,	receiving	12	doses	
of treatment regimen. 






hemoglobin value was not achieved 30 days after treatment com-
pletion.	Similarly,	erythrocytes	and	hematocrit	 showed	a	decrease	
throughout	the	period	of	treatment,	particularly	a	month	after	first	
dose in all groups. The difference among experimental and regular 
treatment	groups	was	statistically	significant.	
table 2: Frequency, and intensity of adverse effects observed on 753 patients treated with MDT
Signs and Symptoms
Absent Mild Moderate Severe Total
N % N % N % N % N %
Skin pigmentation 8298 78.3% 1715 16.2% 572 5.4% 14 0.1% 10599 100%
Xerosis 8813 83.1% 1444 13.6% 297 2.8% 46 0.4% 10600 100%
Itch 10252 96.7% 280 2.6% 56 0.5% 10 0.1% 10598 100%
Headache 10278 97.0% 287 2.7% 34 0.3% 1 0.0% 10600 100%
Paleness 10286 97.0% 284 2.7% 27 0.3% 3 0.0% 10600 100%
Fatigue 10363 97.8% 214 2.0% 20 0.2% 2 0.0% 10599 100%
Myalgia 10389 98.0% 184 1.7% 24 0.2% 3 0.0% 10600 100%
Anorexia 10458 98.7% 118 1.1% 24 0.2% 0 0.0% 10600 100%
Dyspnea 10475 98.8% 109 1.0% 16 0.2% 0 0.0% 10600 100%
Nausea 10484 98.9% 97 0.9% 17 0.2% 2 0.0% 10600 100%
Abdominal pain 10485 98.9% 97 0.9% 13 0.1% 5 0.0% 10600 100%
Weight loss 10496 99.0% 92 0.9% 12 0.1% 0 0.0% 10600 100%
Fever 10499 99.1% 80 0.8% 20 0.2% 0 0.0% 10599 100%
Diarrhea 10524 99.3% 61 0.6% 15 0.1% 0 0.0% 10600 100%
Skin rash 10538 99.4% 41 0.4% 18 0.2% 1 0.0% 10598 100%
Constipation 10545 99.5% 47 0.4% 8 0.1% 0 0.0% 10600 100%
Erythroderma 10548 99.5% 26 0.2% 21 0.2% 5 0.0% 10600 100%
Photodermatosis 10552 99.5% 23 0.2% 24 0.2% 1 0.0% 10600 100%
Depression 10553 99.6% 37 0.3% 8 0.1% 0 0.0% 10598 100%
Bleeding 10562 99.6% 27 0.3% 11 0.1% 0 0.0% 10600 100%
Vomiting 10563 99.7% 26 0.2% 10 0.1% 1 0.0% 10600 100%
Cyanosis 10575 99.8% 17 0.2% 7 0.1% 1 0.0% 10600 100%
Jaundice 10579 99.8% 14 0.1% 7 0.1% 0 0.0% 10600 100%
FIgure 1: 
Changes in transaminases during treat-
ment	in	753	leprosy	patients,	according	
to study groups
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when the mean average between the different groups during treat-
ment	 was	 compared.	 Although	 more	 evident	 in	 the	 PB/U-MDT	




remained high during all treatment. 

















(Drug Reaction with Eosinophilia and Systemic Symptoms – DRESS 
Syndrome).	He	developed	exfoliative	dermatitis,	hepatosplenomeg-






rosy	treatment,	and	most	studies	are	retrospective.5,8 Singh4 et al, did 
one	of	 the	 few	prospective	studies	 to	 investigate	AE;	176	patients	













Serum aminotransferases increased levels was observed in 
272	 (31.5%)	patients.	These	 changes	 could	be	associated	with	any	
of	the	different	component	of	MDT,	but	rifampicin	is	the	most	fre-
quently	related	drug	to	this	AE.	There	was	no	statistical	significant	
difference in the serum aminotransferase levels in the four arms of 
the	study.	No	patient	had	to	stop	rifampicin	or	clofazimine.
Hematological parameters alterations occurred in all groups 
and	statistical	significance	was	observed	between	MB/U-MDT	and	
MB/R-MDT. The faster recovery of hematological parameters ob-
served in the MB/U-MDT group was probably because U-MDT has 
only six doses and there was a long period between the last MDT 
dose and the blood collection accomplished for all MB patients on 
the 13th month after the beginning of MDT. 
Red	blood	cells,	hematocrit	and	hemoglobin	levels	analysis	







Psychiatric disorders 1 4.2%
Sulfone syndrome 1 4.2%
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FIgure 3:  Patient’s	risk	for	ane-
mia according to treatment du-
ration and gender
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according	 to	gender	and	groups	of	 treatment,	presented	significant	
higher decrease on female patients. When Kaplan Meyer analysis was 
performed	only	for	gender,	a	statistically	significant	greater	risk	for	
anemia	was	 observed	on	 females.	Dupnik6 also observed a greater 
risk	for	anemia	related	to	dapsone	in	female	patients.	In	the	present	





that MB patients treated with 6 doses had a higher length of time to 
recover	when	compared	to	those	that	received	12	doses.	Moreover,	it	
is	 important	to	emphasize	the	known	fact	 that	apparently	healthier	




was more evident in the PB/U-MDT group and remained higher 
during the whole treatment; similar results were observed in MB/R-
MDT patients receiving 12 doses. Singh et al4 also	reported	signifi-
cant	increase	in	MCV	and	MCH	parameters	but	different	from	our	
results,	 reported	 statistically	 significant	 decrease	 of	MCHC	 in	pa-
tients receiving MDT.






in a prospective study with 79 patients.4 The intense monitoring of 





arms of the study points to the feasibility of a six-month uniform 
regimen.





The	 shorter	 duration	 of	 U-MDT	 treatment	minimizes	 the	
AE,	namely	those	secondary	to	dapsone.
Monthly	monitoring	enables	early	detection	of	AE,	facilitat-
ing prompt interventions and unnecessary interruption or change 
of treatment.
Based on the present data it is possible to conclude that 
U-MDT is safe and might be implemented at all levels of leprosy 
control program. q
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